Sclerosis News and Research

RSS

Health Alliance, Bayer sign outcomes-based contract to support MS patients

Bayer HealthCare and Health Alliance Medical Plans have entered into an outcomes-based contract for people with relapsing-remitting multiple sclerosis (MS) who are taking Betaseron (interferon beta-1b) to reduce the frequency of clinical exacerbations.

7 Dec 2011

Autism linked with disorganized structure of brain's white matter

It's still unclear what's different in the brains of people with autism spectrum disorders (ASDs), but evidence from genetic and cell studies points to abnormalities in how brain cells (neurons) connect to each other. A study at Children's Hospital Boston now provides visual evidence associating autism with a disorganized structure of brain connections, as well as defects in myelin -- the fatty, insulating coating that helps nerve fibers conduct signals and that makes up the brain's white matter.

6 Dec 2011

Study reveals mechanism of action of laquinimod in patients with RRMS

Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS).

6 Dec 2011

Stem cells for the damaged heart

Stem cell research got its latest boost. For the first time, stem cells were injected into the hearts of humans who had suffered serious heart damage, and patients improved dramatically. The scientists found that the stem cells grew into new heart cells to replace the damaged tissue.

5 Dec 2011

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Mayo Clinic researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis (MS). The findings could lead to better care for the thousands of patients around the world with NMO. The paper was published in the journal, Proceedings of the National Academy of Sciences, USA.

3 Dec 2011

Northwestern researchers receive NIAMSD grant to study scleroderma

Northwestern Medicine researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study scleroderma, an autoimmune disease for which there currently is no cure.

2 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

IOMSN, AANN and ARN publish Nursing Management of the Patient with Multiple Sclerosis guideline

The American Association of Neuroscience Nurses (AANN), the Association for Rehabilitation Nurses (ARN) and the International Organization of Multiple Sclerosis Nurses (IOMSN) are proud to announce the newest addition to the respected AANN Clinical Practice Guideline series, Nursing Management of the Patient with Multiple Sclerosis.

1 Dec 2011

First study to investigate risk factors for CCSVI in patients without neurological disease

The first study to investigate risk factors for the vascular condition called CCSVI (chronic cerebrospinal venous insufficiency) in volunteers without neurological disease has identified what the researchers call a remarkable similarity between this condition and possible or confirmed risk factors for multiple sclerosis.

1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

ACGME approves Cedars-Sinai's neurology residency training program

The Accreditation Council for Graduate Medical Education has approved a neurology residency training program at Cedars-Sinai Medical Center. Recruitment of the first group of three residents is under way through the 2012 "match," a process in which an independent organization pairs applicants with programs to meet the preferences of each.

30 Nov 2011

Kessler Foundation scientists to investigate cognitive reserve in TBI

Denise Krch, PhD, and James Sumowski, PhD, research scientists in the Neuropsychology and Neuroscience Laboratory at Kessler Foundation, received a $379,000 grant for a three-year study of cognitive reserve in people with traumatic brain injury.

30 Nov 2011

Study highlights importance of diagnosing 'overlap syndrome' in sufferers of ALS, FTD

In order to better counsel patients, it is key for clinicians of different disciplines to be aware of, and diagnose, the 'overlap syndrome' between two medical disorders - ALS and FTD - since it significantly affects patient survival. In her new study, Catherine Lomen-Hoerth, from the University of California San Francisco in the US, also highlights that from a research perspective, identifying the syndrome early is an opportunity to study damaged nerve cells and understand more about the early stages of both ALS and FTD.

30 Nov 2011

Counterparts of memory cells ward off microbial foes

The immune system possesses a type of cell that can be activated by tissues within the body to remind the immune system not to attack our own molecules, cells and organs, UCSF researchers have discovered.

29 Nov 2011

Improving patient adherence to medications for chronic diseases can reduce overall treatment costs

Avi Dor, Ph.D., professor in the Department of Health Policy, GW School of Public Health and Health Services, was a co-author of a study, in collaboration with Teva Pharmaceuticals, that found that higher patient adherence to disease modifying therapies, like glatiramer acetate (GA), an immunomodulator drug currently used to treat multiple sclerosis, reduced inpatient costs, outpatient costs, and other medical expenses in a national sample of multiple sclerosis patients.

29 Nov 2011

Neuralstem initiates spinal cord neural stem cell trial in ALS

Neuralstem, Inc. announced that the first patient to receive stem cells in the cervical (upper back) region of the spine was treated on Friday in its ongoing trial to test the safety of its spinal cord neural stem cells in amyotrophic lateral sclerosis.

23 Nov 2011

UCF researchers use stem cells to create nerve-muscle junctions

University of Central Florida researchers, for the first time, have used stem cells to grow neuromuscular junctions between human muscle cells and human spinal cord cells, the key connectors used by the brain to communicate and control muscles in the body.

23 Nov 2011

PAREXEL implements fMRI technology in early phase CNS drug development

PAREXEL International, a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

From Parexel 22 Nov 2011

Scientists discover second faulty gene linked to ALS

Following a major Northwestern Medicine breakthrough that identified a common converging point for all forms of amyotrophic lateral sclerosis (ALS and Lou Gehrig's disease), a new finding from the same scientists further broadens the understanding of why cells in the brain and spinal cord degenerate in the fatal disease.

21 Nov 2011

Sclerosis News and Research

Health Alliance, Bayer sign outcomes-based contract to support MS patients

Autism linked with disorganized structure of brain's white matter

Study reveals mechanism of action of laquinimod in patients with RRMS

Stem cells for the damaged heart

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Northwestern researchers receive NIAMSD grant to study scleroderma

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

IOMSN, AANN and ARN publish Nursing Management of the Patient with Multiple Sclerosis guideline

First study to investigate risk factors for CCSVI in patients without neurological disease

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

ACGME approves Cedars-Sinai's neurology residency training program

Kessler Foundation scientists to investigate cognitive reserve in TBI

Study highlights importance of diagnosing 'overlap syndrome' in sufferers of ALS, FTD

Counterparts of memory cells ward off microbial foes

Improving patient adherence to medications for chronic diseases can reduce overall treatment costs

Neuralstem initiates spinal cord neural stem cell trial in ALS

UCF researchers use stem cells to create nerve-muscle junctions

PAREXEL implements fMRI technology in early phase CNS drug development

Scientists discover second faulty gene linked to ALS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News